Comparing clinical outcomes following 1 year of dual antiplatelet therapy in patients risk stratified by the PRECISE-DAPT and DAPT scores

1 September 2020 (08:30 - 08:30)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Rene Boudreau

University of Ottawa Heart Institute, Ottawa (Canada)

6 More presentations in this session

Presentation thumbnail

First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-986177/JNJ-70033093, a direct, reversible, small molecule Factor XIa inhibitor in healthy volunteers

Doctor V. Perera (Berlin, DE)

Abstract Slides

Presentation thumbnail

S62798, a TAFIa inhibitor, accelerates endogenous thrombolysis in a murine model of pulmonary thromboembolism

Doctor P. Sansilvestri-Morel (Suresnes, FR)

Abstract Slides

Presentation thumbnail

Favorable therapeutic index of an orally-active small-molecule antagonist of the platelet protease-activated receptor-4, BMS-986141, compared with the P2Y12 antagonist ticagrelor in cynomolgus monkeys

Doctor P. Wong (Princeton, US)

Abstract Slides

Presentation thumbnail

Orodispersible ticagrelor use in acute coronary syndrome patients: the Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation (TASTER) Study

Professor G. Parodi (Sassari, IT)

Abstract Slides

Presentation thumbnail

Adherence to dual anti-platelet therapy after acute coronary syndrome and its impact on patient outcome

Doctor P. Sulzgruber (Krems an der Donau, AT)

Abstract Slides

Access the full session

Session thumbnail

Antithrombotic Therapy Update

The Event

ESC Congress 2020

1 September 2020 08:30 CET

You may be interested in

Webinar

Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

Congress Presentation

Antithrombotic therapy in diabetes

Congress Session

State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?